INDUSTRY CONFIDENTIALITY CONCERNS MAY ARISE FROM AIDS DRUG DEVELOPMENT TASK FORCE SURVEY; WORKSHOP ON MOVING DRUGS INTO PHASE I TO BE HELD BY YEAR-END
Executive Summary
Certain questions for industry in the survey of AIDS drag discovery efforts being developed by the National Task Force on AIDS Drug Development could be difficult for manufacturers to answer due to confidentiality concerns, task force member and Bristol-Myers Squibb Senior VP-Clinical R&D Stephen Carter, MD, said at the July 18 task force meeting.